TARGET AUDIENCE The primary target audiences for this initial education include health care providers (physicians, nurse practitioners, and PAs) specializing in hematology, cardiology, neurology, and nephrology. PROGRAM OVERVIEW The aim of this educational program is to enhance clinicians’ knowledge and confidence of treating patients with FXI/FXIa inhibitor therapies. LEARNING OBJECTIVES Outline the limitations of current AC therapies for certain patients and clinical scenarios Discuss the unmet needs for anticoagulation in specific patient populations
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
CME included with membership
| Non-member – Pharmacy SIG Journal Club (per session) | $35 |
| Member – Pharmacy SIG Journal Club (per session) | Free |
| Non-member – 2025 Fundamentals of HCT eBook | $400 |
| Member – 2025 Fundamentals of HCT eBook | $200 |
Collected from the provider’s public pages · source
Specialties served/covered
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Dermatology
- Diagnostic Radiology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Hematology
- Medical Oncology
- Metabolic & Bariatric Surgery
- Nephrology
- Neurology
- Neuromuscular Medicine
- Nuclear Medicine
- Ophthalmology
- Pediatric Neurology
- Pulmonary Disease
- Rheumatology
- Transplant Surgery
- Urological Oncology
- Vascular Neurology
- Cardio-Vascular
- Cross-Specialty
- GI & Liver
- Medical Subspecialties
- Neurology
- Oncology & Hematology
- Pathology & Lab
- Primary care
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Membership pricing — $35–400
This provider prices CME through membership. Individual courses may also be sold separately.
See plans on academy.isth.orgListed by the provider
- Case-based learning
- Credit · Up to 1 credit
- Membership pricing
- Commercial Support
-
ReleasedNov 1, 2025
-
Last day to claim creditMar 1, 2027 5 months left
-
International Society on Thrombosis and Haemostasis +1 Perspectives: What We Are Learning From FXI/FXIa Inhibitor Trials
-
International Society on Thrombosis and Haemostasis +1 Emerging Therapies in Thrombosis: Factor XI/XIa Inhibitors: Learning More: FXI/XIa Inhibitor Trials
-
International Society on Thrombosis and Haemostasis +1 Measuring Up: The Need for New Assays for FXI/FXIa Inhibitor Therapies
-
Medscape, LLC Personalizing Antithrombotic Care: A Case-Based Look at Factor XIa Inhibition After Stroke
-
American College of Cardiology Foundation Beyond DOACs: Exploring the Promise of Factor XI Inhibitors in Cardiovascular Care
-
Answers in CME Inc. (AiCME) What s Next in Anticoagulation? An Evolving Primary Care Playbook for Stroke Prevention in Atrial Fibrillation
